News: Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

10:59am EST
Change (% chg)

kr.-1.70 (-0.38%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks
Select another date:

Wed, Nov 5 2014

BRIEF-Genmab keeps 2014 operating income guidance after Q3

COPENHAGEN, Nov 5 - Danish biotech company Genmab :

BRIEF-Genmab moves cancer drug collaboration to Novartis from GSK

COPENHAGEN, Nov 3 - Genmab A/S : ** Has entered into an agreement with GlaxoSmithKline and Novartis Pharma to transfer the Ofatumumab collaboration with GSK to Novartis ** Novartis will develop and commercialize Ofatumumab in oncology indications and GSK would continue to develop and commercialize ofatumumab for autoimmune indications ** The transfer of the collaboration will not impact Genmab's 2014 financial guidance. Source text for Eikon:

NORDIC STOCKS - Factors to watch on Oct 24

OSLO, Oct 24 - The following stocks may be affected by newspaper reports and other factors on Friday:

BRIEF-Genmab to receive $10 million milestone payment from Janssen

COPENHAGEN, Oct 23 - Genmab A/S : * To receive $10 million milestone payment from Janssen * Milestone from Janssen triggered by progress in the phase III study of daratumumab in combination with bortezomib and dexamethasone * Milestone payment from Janssen is included in genmab's 2014 financial guidance as published on August 13, 2014. Source text for Eikon:

BRIEF-Genmab sees royalty payment of 27 mln DKK for Arzerra in Q3

COPENHAGEN, Oct 22 - Denmark's Genmab A/S said on Wednesday: * Worldwide net sales of Arzerra (ofatumumab) in the third quarter of 2014 totaled 13.8 million pounds ($22.15 million) * Expects royalty payment of approximately 27 million Danish crowns ($4.60 million) Source text for Eikon:

Genmab and Seattle Genetics in antibody drug agreement

COPENHAGEN, Sept 10 - Denmark's Genmab will pay Seattle Genetics $11 million to use its technology with Genmab's AXL antibody and future milestones and royalty payments, as a result of a potential product, could amount to $200 million, the companies said on Tuesday.

Genmab raises 2014 operating income guidance

COPENHAGEN, Aug 13 - Danish biotech company Genmab increased its 2014 operating income guidance to between 175 million and 250 million Danish crowns ($31-45 million) from a previous 140 million to 210 million crowns due to its expectations of higher revenues.

BRIEF-Genmab announces new phase III study of daratumumab

Aug 11 - Genmab A/S : * Announces new phase III study of daratumumab in front line multiple myeloma * Says study expected to start in the first half of 2015 Source text for Eikon:

Select another date:
Search Stocks